A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

References

• World Health Organization. Mental Health: Depression. http://www.who.int/mental_health/management/depression/definition/en/. Accessed 2-15-2012
   Google Scholar
• Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Arch Gen Psychiatry 2005;62:1097-106
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
   PubMed Web of Science ®Google Scholar
• Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007;6:168-76
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011;71:43-64
   PubMed Web of Science ®Google Scholar
• Tranter R, O'Donovan C, Chandarana P, et al. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002;27:241-7
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Hollander E, Nutt D, et al. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 2008;69:246-58
   PubMed Web of Science ®Google Scholar
• Warden D, Rush A, Trivedi M, et al. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59
   PubMedGoogle Scholar
• Moller HJ. Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry 2008;9:102-14
   PubMed Web of Science ®Google Scholar
• Papakostas GI. The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry 2010;71(Suppl E1):e03
   Google Scholar
• Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr 2007;12:1-27
   PubMed Web of Science ®Google Scholar
• Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289-304
   PubMed Web of Science ®Google Scholar
• Schechter LE, Ring RH, Beyer CE, et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRX 2005;2:590-611
   PubMedGoogle Scholar
• Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54:3206-21
   PubMed Web of Science ®Google Scholar
• Mork A, Pehrson A, Tottrup Brennum L, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012;340:666-75
   PubMed Web of Science ®Google Scholar
• Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int Jf Neuropsychopharmacol 2012;15:589-600
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-91
   PubMed Web of Science ®Google Scholar
• Henigsberg N, Mahableshwarkar A, Jacobsen P, et al. Efficacy and tolerability of multiple doses of Lu AA21004 in an 8-week trial of adults with major depressive disorder. J Clin Psychiatry 2012; in press
   Google Scholar
• Boulenger JP, Loft H, Florea I. A double -blind, randomized, placebo -controlled, multicenter, relapse -prevention study with two doses of Lu AA21004 in patients with MDD. J Psychopharmacol 2012;26:1408-16
   PubMed Web of Science ®Google Scholar
• Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-week trial of the efficacy and tolerability of vortioxetine 5 mg in adults with major depressive disorder. Int J Neuropsychopharmacol First View 2012;1-9. DOI: 10.1017/S1461145712000727
   Google Scholar
• Katona C, Hansen T, Olsen CK. A randomised, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27:215-23
   PubMed Web of Science ®Google Scholar
• McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40
   PubMed Web of Science ®Google Scholar
• Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-92
   PubMed Web of Science ®Google Scholar
• Khan A, Bhat A, Kolts R, et al. Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther 2010;16:217-26
   PubMed Web of Science ®Google Scholar
• Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 2011;72:464-72
   PubMed Web of Science ®Google Scholar
• Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 2002;5:193-7
   PubMed Web of Science ®Google Scholar
• Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry 2001;16:418-23
   PubMed Web of Science ®Google Scholar
• Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-7
   PubMed Web of Science ®Google Scholar
• Khan A, Detke M, Khan SR, et al. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 2003;191:211-18
   PubMed Web of Science ®Google Scholar
• Goldstein DJ. Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2007;3:193-209
   PubMedGoogle Scholar
• Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003;28:552-7
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Tamura RN, Tanaka Y. Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. J Psychiatr Res 2011;45:1202-7
   PubMed Web of Science ®Google Scholar
• Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010;71:270-9
   PubMed Web of Science ®Google Scholar
• Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry 2007;190:287-92
   PubMed Web of Science ®Google Scholar
• Kobak KA, Leuchter A, DeBrota D, et al. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol 2010;30:193-7
   PubMed Web of Science ®Google Scholar
• Shen J, Kobak KA, Zhao Y, et al. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. J Clin Psychopharmacol 2008;28:691-3
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Lane PW, Schnell D, et al. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inform J 2008;42:303-19
   Web of Science ®Google Scholar
• Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009;19:227-46
   Google Scholar